Retraction Note: Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer (Oncogene, (2014), 33, 42, (4985-4996), 10.1038/onc.2013.444);Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer

Oncogene

Volumn 33, Issue 42, 2014, Pages 4985-4996

  Zheng, X Q ^a,b   Guo, J P ^a   Yang, H ^a   Kanai, M ^a   He, L L ^a   Li, Y Y ^a   Koomen, J M ^a   Minton, S ^a   Gao, M ^b   Ren, X B ^b   Coppola, D ^a   Cheng, J Q ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

Aurora A; ER ; phosphorylation; tamoxifen resistance; transcriptional activation

Indexed keywords

ALISERTIB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AURKA PROTEIN, HUMAN; AURORA A KINASE; AZEPINE DERIVATIVE; CCND1 PROTEIN, HUMAN; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; PYRIMIDINE DERIVATIVE; TAMOXIFEN;

ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NUDE MOUSE; PHOSPHORYLATION; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROTEIN PROCESSING; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AURORA KINASE A; AZEPINES; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN D1; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; MICE, NUDE; PHOSPHORYLATION; PROPORTIONAL HAZARDS MODELS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIMIDINES; TAMOXIFEN; TRANSCRIPTIONAL ACTIVATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85027947011     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/s41388-024-02983-9     Document Type: Erratum

References (45)

1. Warner SL, Bearss DJ, Han H, Von Hoff DD. Targeting Aurora-2 kinase in cancer. Mol Cancer Ther 2003; 2: 589–595. DOI: 10.4161/cbt.2.5.506
2. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3: 51–62. DOI: 10.1016/S1535-6108(02)00235-0
3. Bodvarsdottir SK, Hilmarsdottir H, Birgisdottir V, Steinarsdottir M, Jonasson JG, Eyfjord JE. Aurora-A amplification associated with BRCA2 mutation in breast tumours. Cancer Lett 2007; 248: 96–102. DOI: 10.1016/j.canlet.2006.06.003
4. Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL, Li SA. Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci USA 2004; 101: 18123–18128. DOI: 10.1073/pnas.0408273101
5. Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 2006; 25: 7148–7158. DOI: 10.1038/sj.onc.1209707
6. D’Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M, Leontovich A et al. The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERalpha(+) breast cancer cells. Oncogene 2014; 33: 599–610. DOI: 10.1038/onc.2012.628
7. Wang LH, Xiang J, Yan M, Zhang Y, Zhao Y, Yue CF et al. The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway. Cancer Res 2010; 70: 9118–9128. DOI: 10.1158/0008-5472.CAN-10-1246
8. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474–1481. DOI: 10.1200/JCO.1999.17.5.1474
9. Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001; 7: 4338s–4342s discussion 411s–412s.
10. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001; 29: 2905–2919. DOI: 10.1093/nar/29.14.2905
11. Jordan VC, O’Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007; 25: 5815–5824. DOI: 10.1200/JCO.2007.11.3886
12. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003; 22: 7316–7339. DOI: 10.1038/sj.onc.1206937
13. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631–643. DOI: 10.1038/nrc2713
14. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11: 643–658. DOI: 10.1677/erc.1.00776
15. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995; 55: 3331–3338.
16. Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T et al. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev 2010; 24: 2219–2227. DOI: 10.1101/gad.1944810
17. Nagashima T, Shimodaira H, Ide K, Nakakuki T, Tani Y, Takahashi K et al. Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation. J Biol Chem 2007; 282: 4045–4056. DOI: 10.1074/jbc.M608653200
18. Yang H, Ou CC, Feldman RI, Nicosia SV, Kruk PA, Cheng JQ. Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res 2004; 64: 463–467. DOI: 10.1158/0008-5472.CAN-03-2907
19. Cutrupi S, Reineri S, Panetto A, Grosso E, Caizzi L, Ricci L et al. Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells. Oncogene 2012; 31: 4353–4361. DOI: 10.1038/onc.2011.627
20. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 2011; 17: 7614–7624. DOI: 10.1158/1078-0432.CCR-11-1536
21. Tonetti DA, Jordan VC. Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Anticancer Drugs 1995; 6: 498–507. DOI: 10.1097/00001813-199508000-00002
22. Murphy LC, Seekallu SV, Watson PH. Clinical significance of estrogen receptor phosphorylation. Endocr Relat Cancer 2011; 18: R1–14. DOI: 10.1677/ERC-10-0070
23. Ferrari S, Marin O, Pagano MA, Meggio F, Hess D, El-Shemerly M et al. Aurora-A site specificity: a study with synthetic peptide substrates. Biochem J 2005; 390: 293–302. DOI: 10.1042/BJ20050343
24. Bostner J, Ahnstrom Waltersson M, Fornander T, Skoog L, Nordenskjold B, Stal O. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 2007; 26: 6997–7005. DOI: 10.1038/sj.onc.1210506
25. Lundgren K, Brown M, Pineda S, Cuzick J, Salter J, Zabaglo L et al. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res 2012; 14: R57. DOI: 10.1186/bcr3161
26. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat 2010; 123: 725–731. DOI: 10.1007/s10549-009-0674-9
27. Guo JP, Shu SK, Esposito NN, Coppola D, Koomen JM, Cheng JQ. IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer. J Biol Chem 2010; 285: 3676–3684. DOI: 10.1074/jbc.M109.078212
28. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001; 276: 9817–9824. DOI: 10.1074/jbc.M010840200
29. Holz MK. The role of S6K1 in ER-positive breast cancer. Cell Cycle 2012; 11: 3159–3165. DOI: 10.4161/cc.21194
30. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 1998; 18: 1978–1984. DOI: 10.1128/MCB.18.4.1978
31. Barkhem T, Nilsson S, Gustafsson JA. Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J Pharmacogenomics 2004; 4: 19–28. DOI: 10.2165/00129785-200404010-00003
32. Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir JM, Corbo L. Cracking the estrogen receptor’s posttranslational code in breast tumors. Endocr Rev 2011; 32: 597–622. DOI: 10.1210/er.2010-0016
33. Wang RA, Mazumdar A, Vadlamudi RK, Kumar R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J 2002; 21: 5437–5447. DOI: 10.1093/emboj/cdf543
34. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 2004; 5: 597–605. DOI: 10.1016/j.ccr.2004.05.016
35. Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J et al. Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol 2009; 217: 372–379. DOI: 10.1002/path.2455
36. Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van’t Veer LJ et al. PKA-induced phosphorylation of ERalpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 2011; 125: 1–12. DOI: 10.1007/s10549-010-0798-y
37. Bostner J, Skoog L, Fornander T, Nordenskjöld B, Stål O. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res 2010; 16: 1624–1633. DOI: 10.1158/1078-0432.CCR-09-1733
38. Ohishi T, Hirota T, Tsuruo T, Seimiya H. TRF1 mediates mitotic abnormalities induced by Aurora-A overexpression. Cancer Res 2010; 70: 2041–2052. DOI: 10.1158/0008-5472.CAN-09-2008
39. Lim KH, Brady DC, Kashatus DF, Ancrile BB, Der CJ, Cox AD et al. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol Cell Biol 2010; 30: 508–523. DOI: 10.1128/MCB.00916-08
40. Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 2004; 279: 52175–52182. DOI: 10.1074/jbc.M406802200
41. Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell 2007; 129: 1351–1363. DOI: 10.1016/j.cell.2007.04.035
42. Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Manziolli A et al. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol 2011; 81: 881–890. DOI: 10.1016/j.bcp.2011.01.017
43. Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecsedy J et al. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther 2012; 11: 763–774. DOI: 10.1158/1535-7163.MCT-11-0623
44. Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 1994; 54: 1587–1595.
45. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440–446. DOI: 10.1158/0008-5472.CAN-09-1947